NICE TAs

04/11/2026

HST36: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over (review of HST31)

04/11/2026

TA1206: Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more lines of systemic treatment

30/10/2026

TA1205: maralixibat for treating cholestatic pruritus in Alagille syndrome in people 2 months and over

28/10/2026

TA1204: Plozasiran for treating familial chylomicronaemia syndrome

28/10/2026

TA1203: Olezarsen for treating familial chylomicronaemia syndrome

20/10/2026

TA1202: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment

13/10/2026

TA1198: Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer (terminated evaluation)

07/10/2026

TA1197: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

30/09/2026

TA1195: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable

24/09/2026

TA1194: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

23/09/2026

TA1193: Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable

16/09/2026

TA1192: Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years

09/09/2026

TA1191: Nemolizumab for treating moderate to severe prurigo nodularis

09/09/2026

TA1190: Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer

26/08/2026

TA1189: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

25/08/2026

TA1188: Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)

21/08/2026

TA1187: Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation)

21/08/2026

TA1186: Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)

19/08/2026

TA1185: Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia

19/08/2026

TA1184: Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma